T o establish the prognosis of heart failure (HF), several biomarkers are currently used, such as natriuretic peptides (eg, brain natriuretic peptide [BNP] , N-terminal probrain natriuretic peptide [NT-proBNP] ). Recently, galectin-3 was approved by the US Food and Drug Administration as a new biomarker in HF risk stratification. Galectin-3 is a β-galactoside-binding lectin and is best known for its role as a mediator of tumor growth and metastasis. 1 In addition to its role in tumorigenesis, galectin-3 plays a role in inflammatory and immune-mediated disorders, 2, 3 as well as in fibrogenesis, [4] [5] [6] [7] mechanisms involved in the progression of HF and cardiac remodeling. 8, 9 Clinical Perspective on p 226
The clinical use of a single measurement of galectin-3 for the diagnosis of HF has been demonstrated previously, 10 as well as its use as a predictor for left ventricular remodeling 11 and mortality and adverse outcomes in various patient cohorts, with both acute and chronic HF or after the event of an acute coronary syndrome. [12] [13] [14] [15] [16] [17] [18] Besides its prognostic value in patients, galectin-3 also predicts all-cause mortality in the general population. 19 However, 1 study in ambulatory patients with HF, where a low cutoff value of galectin-3 was used (14.0), did not show the same association between galectin-3 and long-term outcome in patients with HF after adjustment for other predictors, especially NT-proBNP.
has been reported that galectin-3 level predicts the response to statin therapy. 21 A limitation to the published studies is that they all describe the value of a single (baseline) measurement of galectin-3 on prognosis. Clearly, a biomarker reflects the disease process and is expected to fluctuate in accordance with disease severity. Several studies have reported an increased prognostic value of repeated measurements of biomarkers, such as natriuretic peptides. [22] [23] [24] [25] Repeated measurements of galectin-3 may also provide additional prognostic information on near-to long-term outcomes, may guide decisions for optimal HF management, and predict the clinical stabilization of individual patients. Until now, the clinical use of repeated measurements of galectin-3 has not been reported. Accordingly, the aim of this study was to evaluate the prognostic value of repeated galectin-3 measurements in patients with chronic HF, enrolled in 2 large prospective clinical trials.
Methods

Patient Population
Patients with HF in these substudies were enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) [NCT00206310] (n=1329), a cohort of patients with chronic HF (New York Heart Association II+), and the Coordinating Study Evaluating Outcomes of Advising and Counseling Failure (COACH) [NCT98675639] (n=324), a cohort of acutely decompensated patients with HF. The design and outcomes of these trials have been published elsewhere. [26] [27] [28] [29] All patients had baseline and 3-month (CORONA patients) and 6-month (COACH patients) follow-up blood samples available for galectin-3 measurements. In COACH, samples at baseline were obtained 1 day before discharge.
Measurement of Galectin-3
Plasma galectin-3 levels were measured using a commercial assay (the BG Medicine galectin-3 Assay; BG Medicine, Waltham, MA), the characteristics of which have been described in detail earlier. 30 This assay quantitatively measures the concentration of human galectin-3 levels in EDTA plasma and has been shown to have high sensitivity (with a lower detection limit of 1.13 ng/mL) and no cross-reactivity with other members of the galectin family, or with other collagens, and no known interference by commonly used HF medications. Intraand interassay coefficients of variation were 5.6% and 8.6%, respectively. To categorize patients, a threshold value of galectin-3 of 17.8 ng/mL was applied, based on the US Food and Drug Administration-cleared assay labeling for risk stratification using this assay. This cutoff value was based on unpublished data from a controlled multicenter clinical study, the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial, where 2331 chronic HF patients with left ventricular dysfunction and with New York Heart Association class II, III, or IV symptoms were studied, as has been shown in the Galectin-3 ELISA Package Insert (US), BG Medicine, Inc.
Primary End Point
The primary end point was the composite of all-cause mortality and rehospitalizations during follow-up. Rehospitalization was defined as an unplanned overnight stay in the hospital attributable to worsening HF.
Secondary End Points
Secondary end points included all-cause mortality as independent end point, as well as the composite of cardiovascular mortality and HF hospitalization (this end point was available for CORONA only). Analyses were adjusted for baseline covariates of age, sex, diabetes mellitus, left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), and NT-proBNP level.
Statistical Analysis
In comparisons of baseline characteristics across categories, differences among categorical variables reported as means and SD were calculated using χ 2 tests. Temporal changes in galectin-3 levels were considered in statistical analyses by 2 different approaches. First, changes in galectin-3 were categorized based on the cutoff value of 17.8 ng/mL to yield 4 patient categories as follows: (1) low→low (<17.8 at both time points), (2) high→low (level >17.8 ng/mL at baseline and <17.8 ng/mL at the subsequent time point [3 months for CORONA, 6 months for COACH]), (3) low→high (<17.8 ng/ mL at baseline and >17.8 ng/mL at the subsequent time point), and (4) high→high (>17.8 ng/mL at both time points). Second, continuous percentage change in galectin-3 level between the 2 visits were categorized as follows: (1) patients whose galectin-3 level increased ≥15% over time, (2) patients whose galectin-3 level decreased ≤15% or more over time, and (3) patients with galectin-3 levels remaining within ±15% of baseline value (change between −15% and + 15%). The choice of a threshold of 15% was based on the intra-and interassay coefficients of variation of 5.6% and 8.6%, respectively; a change of approximately twice the coefficient of variation was decided to be satisfactory. In addition, for the COACH study, a receiver operating characteristic curve analysis of relative change in galectin-3 on the end point of all-cause mortality and all-cause hospitalization yielded a maximum value for the sum of sensitivity and specificity at a value of 13.9% change. Taken together, the threshold change value of 15% was selected.
The independent prognostic value of categories of percentage change of galectin-3 for each end point was assessed in Cox proportional hazards models. Multivariable models adjusted for baseline covariates of galectin-3, age, sex, diabetes mellitus, LVEF, eGFR, and NT-proBNP levels were also assessed. Covariates that were univariately associated with the outcomes were included in the multivariable models (Table S1 in the online-only Data Supplement). Cumulative incidence plots were generated to visualize the probability of event as a function of time intervals. Cox proportional hazards regression models incorporating galectin-3 categories and adjusted for baseline galectin-3 were fitted to estimate baseline galectin-3 adjusted survival functions, which were then visualized in cumulative incidence plots.
All statistical analyses were performed at a significance level of 0.05. Analyses were performed with SAS software, version 9.1 (SAS Institute, Inc, Cary, NC), or R software, version 2.
Results
Study Population
A total of 1653 patients (1329 from the CORONA trial and 324 from the COACH trial), and associated galectin-3 measurements were available for the present study. Baseline, and 3-(CORONA trial) and 6-month (COACH trial) follow-up galectin-3 measurements were available in all patients. The mean age of the study participants of CORONA and COACH was 71.6 years (±6.8) and 69.9 years (±11.5), respectively. In both studies, the large majority of the patients were men (77% and 60%, respectively). Mean LVEF was 32% (±7) in CORONA and 33% (±14) in COACH. The mean eGFR was 58.1 mL/min (±2.9) in CORONA and 57.1 mL/min (±17.0) in COACH. Mean levels of galectin-3 at baseline were 20.2 ng/mL (±7.6) in CORONA, and in COACH 20.4 ng/mL (±8.8). In this study, the total assay variation in measurement of galectin-3 was <6.3%. Baseline demographics and clinical characteristics of both sets of patients are presented in Table 1 .
Changes in Categorical Galectin-3 Levels
Categorical changes in galectin-3 level between baseline and the subsequent time point were defined, based on the suggested threshold value of 17.8 ng/mL in the Food and Drug Administration-cleared labeling for galectin-3. Changes in galectin-3 category between the 2 time point measurements, either increasing or decreasing, were observed in 17.3% and 23.5% of patients enrolled in the CORONA and COACH trials, respectively ( Figure S1 in the online-only Data Supplement). Baseline characteristics of these patients, by category of change, in both CORONA and COACH are presented in Tables S2 and S3 in the online-only Data Supplement. Among CORONA subjects, those patients with initially low baseline galectin-3 levels that increased by 3 months (<17.8 ng/mL to >17.8 ng/mL) were comparable with patients whose initial galectin-3 levels were high, but decreased over time, in age (70.8 versus 70.9 years), and in disease severity measures, including New York Heart Association class (71% III/IV versus 66% III/IV), LVEF (31% versus 32%), and NT-proBNP (1762 versus 1690 pg/mL). A similar pattern was seen in the COACH subjects, although those with galectin-3 category increasing over time were older than those with decreasing galectin-3 (76.8 versus 67.1 years) ( Table S3 in the onlineonly Data Supplement).
As shown in Figure 1 , patients with initial galectin-3 levels <17.8 ng/mL that increased over time to >17.8 ng/mL were seen to have significantly worse outcomes in all-cause mortality and HF hospitalization than patients whose galectin-3 levels remained <17.8 ng/mL, in both the CORONA and COACH studies (hazard ratio [HR] in CORONA, 1.53; 95% confidence interval [CI], 1.10-2.13; P=0.011; HR in COACH, 2.38; 95% CI, 1.02-5.55; P=0.046). Reversely, patients with high baseline galectin-3 levels that decreased over time past the threshold of 17.8 ng/mL had a significantly lower rate of all-cause mortality and HF hospitalization events than patients whose galectin-3 levels that were high at baseline and remained >17. 
Percentage Change in Galectin-3 Levels
To corroborate our findings, we repeated analyses but used relative change instead of categorical changes. Changes in galectin-3 levels over time were categorized by the magnitude of change calculated as the percent increase or decrease from baseline value. Among the CORONA trial patients with galectin-3 measurements, 241 experienced an increase in galectin-3 level of >15% from baseline, whereas 233 patients had a decrease of ≤15%, and 855 patients stayed within 15% of their baseline galectin-3 level ( Table 2) . As shown in Figure 2A and in Table 3 , an increase of ≥15% in galectin-3 value from baseline to 3 months, adjusted for baseline level, was found to correspond to a significant 50% higher risk of mortality and HF hospitalization compared with patients with stable values of galectin-3 in the same time frame, independent of age, sex, diabetes mellitus, LVEF, eGFR, and NT-proBNP in CORONA (HR, 1.500; 95% CI, 1.173-1.917; P=0.001). Similar results were observed for the end points of cardiovascular mortality and HF hospitalization, and allcause mortality (Table 3) . Addition of medication (angiotensin converting enzyme inhibitor, β-blocker, angiotensin receptor blocker) to the multivariate model did not materially change these findings (Table S4 in the online-only Data Supplement). Although the category comprising patients experiencing a decrease of ≤15% in galectin-3 level from baseline did show a trend toward lower event rate (Figure 2A) , the difference compared with patients who remained within 15% of their baseline level did not reach statistical significance (Table 3) .
Among patients from the COACH study, 58 subjects had an increase in galectin-3 levels of >15%, 147 had a decrease of ≤15%, and 119 remained within ±15% of the baseline level ( Table 4) . As shown in Figure 2B and in Table 3 , patients whose galectin-3 levels increased by ≥15% over time experienced the outcome of all-cause mortality and HF hospitalization at nearly twice the event rate as subjects with relatively more stable galectin-3 levels, independent of age, sex, diabetes mellitus, LVEF, eGFR, and NT-proBNP level (HR, 1.973; 1.026-3.794; P=0.042; Table 3 ). Finally, to provide further insight whether change in galectin-3 provides additional information compared with baseline galectin-3 alone, we compared a prognostic model including baseline galectin-3 to a prognostic model including percent change in galectin-3 (both models corrected for age, sex, diabetes mellitus, LVEF, eGFR, and NT-proBNP), using a specific statistical method. 31 It was observed that the model with percent change in galectin-3 seems to have better discrimination than the model with baseline galectin-3 alone (Table 5) .
Discussion
This study demonstrates, in 2 independent patient cohorts with HF, that patients with low baseline galectin-3 levels that increased during a follow-up period of 3 to 6 months have significantly worse outcomes than those who maintained a low galectin-3 level. Similarly, patients with high initial galectin-3 levels that remained high during a time scale of months had significantly worse outcomes than those whose levels decreased over time. In total, categorical changes in galectin-3 occurred in approximately one fifth of patients during follow-up.
Previously, it was demonstrated that a single determination of galectin-3 level during hospital admission had prognostic value in various HF patient populations, especially regarding mortality and HF rehospitalizations. [12] [13] [14] [15] [16] [17] [18] This present study extends these findings by demonstrating that repeated measurements of galectin-3 levels provide additional prognostic value in identifying patients with HF at elevated risk for subsequent HF morbidity and mortality. Although 1 relatively small study in patients with chronic HF (n=200) concluded that serial measuring of BNP, after an initial elevation, may not be useful for better risk stratification, 32 our results are in *Decrease >15% means galectin-3 decrease by −15% or greater between baseline and at 3 months. †Increase >15% means galectin-3 increase by +15% or greater between baseline and at 3 months. ACE indicates angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HF, heart failure; IQR, interquartile range (25th to 75th percentile range); no., number (count of subjects); NT-pro BNP, N-terminal probrain natriuretic peptide; and NYHA, New York Heart Association.
line with results of studies that evaluated the prognostic value of repeated measurements of BNP and NT-proBNP. 23, 25 We studied 2 different HF cohorts. However, similarities in outcomes were remarkable, which strengthens the generalizability of our findings. Baseline galectin-3 levels were almost identical in the 2 cohorts studied; CORONA: 20.2 (±7.6) ng/mL, and COACH 20.4 (±8.8) ng/mL, although slightly lower during follow-up in COACH: 18.2 (±9.9) ng/mL compared with CORONA 20.1 (±7.6) ng/mL. Baseline levels of NT-proBNP were 1514 pg/mL in CORONA and 2163 pg/mL in COACH. These values reflect the severity of HF in COACH (acute HF patients) and in CORONA (chronic HF patients, with New York Heart Association II or greater). The population in COACH consists of patients who were admitted for acute decompensated HF. This may explain the high number of patients in the high→low category in COACH, indicating that many patients had high galectin-3 levels during the period of enrollment, with galectin-3 levels gradually decreasing over time. Although galectin-3 is known to be a slow marker, 33 meaning galectin-3 levels do not readily respond to unloading or other therapy, galectin-3 levels did show a decreasing trend when patients returned to recompensated state. However, a decrease of galectin-3 to <17.8 ng/mL did not show a statistically significant improvement in prognosis. This might be explained by the relative small subset of patients with a decrease (resulting in low statistical power), but also by the fact that galectin-3 has been shown previously to be a marker of fibrogenesis and as such deleterious effects of galectin-3-induced fibrosis may be difficult to reverse.
Galectin-3 levels of CORONA patients tended to be more stable, which may reflect the more stable patient cohort. In terms of predicting value, both the categorical and relative percent changes conferred strikingly comparable prognostic consequences in both cohorts. It would be interesting to confirm our findings in another large verification cohort.
As discussed, galectin-3 has little or no response to volume unloading. 33 This is very different from natriuretic peptides, which respond directly to volume overload and unloading. It remains speculative what the main driver of the changes in galectin-3 levels may be. Recently, it has been shown that galectin-3 is modulated by genetic variances 34 ; however, it is unknown what factors control galectin-3. Galectin-3 is known to be involved in progression of myocardial fibrosis, 8 is secreted by macrophages in the heart, 35 and also in other organs, such as the kidneys and vasculature. The observed variation in galectin-3 in these 2 cohorts, associated with substantially different prognosis, may reflect changes in cardiac-derived galectin-3 production, but it also could reflect changes in galectin-3 production in other organs. Regardless of its origin, the observed changes exhibited important prognostic consequences.
Clinical Implications
A clinical advantage of the use of galectin-3 as a biomarker is that values at any time point powerfully predict outcome based on a single cutoff value of levels with little interindividual variation. For instance, natriuretic peptides are associated with wider interindividual variability, making use of a single cutoff value challenging. Our data suggest that changes in galectin-3 may provide useful additional prognostic information. Patients who have an increase, either a 15% increase or an increase from below to above 17.8 ng/mL, have a profoundly worse prognosis than patients who have stable or decreasing galectin-3 levels. Increased galectin-3 levels probably reflect disease progression. It is interesting to speculate that targeted treatment aimed at lowering galectin-3 may improve prognosis. We recently published that, in experimental HF models, galectin-3 inhibition attenuates HF development. 36 Furthermore, activation of the mineralocorticoid receptor has been shown to promote cardiac fibrosis. 37 Recently published preclinical data have shown that aldosterone-induced vascular fibrosis is galectin-3 dependent. Interestingly, both the use of the mineralocorticoid receptor antagonist, spironolactone, and the galectin-3 inhibitor modified citrus pectin inhibited aldosterone-induced fibrosis. 38 Therefore, it would be interesting to study the effect of mineralocorticoid receptor antagonists in patients with elevated levels of galectin-3. Such a galectin-3-guided study may provide more insight into the importance of galectin-3 in HF pathophysiology. Given the biological effects of galectin-3, it would also be interesting to incorporate this parameter in the study of biomarkers of fibrosis and inflammation. *Decrease >15% means galectin-3 decrease by −15% or greater between baseline and at 3 months. †Increase >15% means galectin-3 increase by +15% or greater between baseline and at 3 months. ACE indicates angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; COACH, Coordinating Study Evaluating Outcomes of Advising and Counseling Failure; GFR, glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; IQR, interquartile range (25th to 75th percentile range); no., number (count of subjects); NT-proBNP, N-terminal probrain natriuretic peptide; and NYHA, New York Heart Association.
Limitations
Limitations of this study include a potential lack of power, in particular in the COACH cohort; however, by combining 2 studies we attempted to overcome this limitation. Galectin-3 was measured at different time points in these studies (3 months CORONA versus 6 months COACH), which presents another limitation. Although galectin-3 is known to be a slow marker, time could have influenced the level of galectin-3 and may explain the lower level of galectin-3 during follow-up in COACH. The relationship between changes in galectin-3 and changes in other parameters (eg, NT-proBNP, eGFR) could not be studied because a postbaseline value of creatinine or BNP/NT-proBNP was not available, or was in very low numbers. As such, while of great interest, these relationships remain unknown.
Conclusions
In conclusion, we show that changes in galectin-3 level provided important and significant prognostic value in identifying patients with HF at elevated risk for subsequent HF morbidity and mortality in 2 large independent cohorts of patients with HF. Future prospective studies should identify whether it is clinically useful to monitor galectin-3 over time and whether it is possible to apply galectin-3-targeted treatment or regimens. The area under the receiver operating characteristic (AUROC) was calculated for 2 models: one with baseline galectin-3 levels and one with change in galectin-3 levels. All results are for the primary composite end point of heart failure hospitalization or mortality, first to occur.
CI indicates confidence interval; COACH, Coordinating Study Evaluating Outcomes of Advising and Counseling Failure; and CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure.
